Traditional and Recurrent Spheno-Orbital Meningioma (SOM) Comparison and Treatment Methods
DOI:
https://doi.org/10.62051/q186ws19Keywords:
Spheno-orbital meningioma; SOM tumor biology; SOM treatments.Abstract
Spheno-orbital meningiomas (SOM) are rare brain tumors that pose significant challenges to treatments due to their anatomical complexity and high recurrence rates. This literature review considers journals published between 2000 and 2024. Analysis will be drawn based on current surgical and nonsurgical interventions of primary and recurrent SOMs and emerging treatments. Besides that, the review will draw an in-depth description of genetic mutations, such as NF2 and PI3K/AKT/mTOR pathway activation; surgical techniques such as MTA, EEA, and ETOA; and factors contributing to increased recurrent risks. Although treatment options for SOM continue to advance, complete resection is still difficult to achieve, especially in patients with recurrent SOMs. Understanding the tumor biology, pathogenesis, and limitations in current treatments allows for more accurate and effective treatments.
Downloads
References
[1] Patel, A. Benign vs malignant tumors. Journal of the American Medical Association Oncology, 2020, 6 (9): 1488. DOI: https://doi.org/10.1001/jamaoncol.2020.2592
[2] Koya, A. I., & Ibrahim, S. A. Carcinogenesis. StatPearls, 2024. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK604463.
[3] Ostrom, Q. T., Cioffi, G., Waite, K., et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014 – 2018. Neuro-Oncology, 2021, 23 (Suppl 3): iii1 – iii105. DOI: https://doi.org/10.1093/neuonc/noab200
[4] Eguiluz-Melendez, A., Rodríguez-Hernández, L. A., López-Molina, J. A., et al. Obstructive hydrocephalus due to posterior fossa tumors in adults: A comparative analysis of 3 surgical techniques. World Neurosurgery, 2023, 175: e593 – e600. DOI: https://doi.org/10.1016/j.wneu.2023.03.147
[5] Ogasawara, C., Philbrick, B. D., & Adamson, D. C. Meningioma: A review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines, 2021, 9 (3): 319. DOI: https://doi.org/10.3390/biomedicines9030319
[6] Evans, D. R. Neurofibromatosis type 2 (NF2): A clinical and molecular review. Orphanet Journal of Rare Diseases, 2009, 4: 16. DOI: https://doi.org/10.1186/1750-1172-4-16
[7] Alruwaili, A., & De Jesus, O. Meningioma. StatPearls, 2023.
[8] Saloner, D., Uzelac, A., Hetts, S., et al. Modern meningioma imaging techniques. Journal of Neuro-Oncology, 2010, 99 (3): 333 – 340. DOI: https://doi.org/10.1007/s11060-010-0367-6
[9] Takase, H., & Yamamoto, T. Bone invasive meningioma: Recent advances and therapeutic perspectives. Frontiers in Oncology, 2022, 12: 895374. DOI: https://doi.org/10.3389/fonc.2022.895374
[10] Krengli, M., Apicella, G., Deantonio, L., et al. Stereotactic radiation therapy for skull base recurrences: Is a salvage approach still possible? Reports of Practical Oncology and Radiotherapy, 2015, 20 (6): 430 – 439. DOI: https://doi.org/10.1016/j.rpor.2014.10.007
[11] Nagahama, A., Goto, T., Nagm, A., et al. Spheno-orbital meningioma: Surgical outcomes and management of recurrence. World Neurosurgery, 2019, 126: e679 – e687. DOI: https://doi.org/10.1016/j.wneu.2019.02.123
[12] Wierzbowska, J., Zegadło, A., Patyk, M., et al. Spheno-orbital meningioma and vision impairment—Case report and review of the literature. Journal of Clinical Medicine, 2022, 12 (1): 74. DOI: https://doi.org/10.3390/jcm12010074
[13] Forrester, J. V., Dick, A. D., McMenamin, P. G., et al. Anatomy of the eye and orbit. The Eye: Basic Sciences in Practice, 2016: 1 – 102. DOI: https://doi.org/10.1016/B978-0-7020-5554-6.00001-0
[14] Ricciuti, V., Peppucci, E., Montalbetti, A., et al. Endoscopic transorbital approach for recurrent spheno-orbital meningiomas: Single center case series. Neurosurgical Review, 2024, 47 (1): 706. DOI: https://doi.org/10.1007/s10143-024-02905-z
[15] Elborady, M. A., & Nazim, W. M. Spheno-orbital meningiomas: Surgical techniques and results. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57: 18. DOI: https://doi.org/10.1186/s41983-021-00276-6
[16] Lee, S., Karas, P. J., Hadley, C., et al. The role of Merlin/NF2 loss in meningioma biology. Cancers, 2019, 11 (11): 1633. DOI: https://doi.org/10.3390/cancers11111633
[17] Smith, J., & Doe, J. A rare case of spheno-orbital meningioma presenting with visual impairment. Cureus, 2024.
[18] Saito, K., Nishimura, Y., Takemura, Y., et al. Extensive extracranial growth of spheno-orbital meningioma: Illustrative case. Journal of Neurosurgery: Case Lessons, 2023, 5 (7): CASE22322. DOI: https://doi.org/10.3171/CASE22322
[19] Salehi, F., Jalali, S., Alkins, R., et al. Proteins involved in regulating bone invasion in skull base meningiomas. Acta Neurochirurgica, 2013, 155 (3): 421 – 427. DOI: https://doi.org/10.1007/s00701-012-1577-9
[20] Srivastava, O., Plemel, D. J. A., Tong, C. M., et al. Anaplastic spheno-orbital meningioma: Rapid growth after extensive exenteration. Canadian Journal of Ophthalmology, 2023, 58 (2): e92 – e95. DOI: https://doi.org/10.1016/j.jcjo.2022.07.004
[21] Sahm, K., Schrimpf, F., Perry, D., et al. Meningioma: Current updates on genetics, classification, and mouse models. Upsala Journal of Medical Sciences, 2022, 127: 10579.
[22] Liu, Y., Li, F., Wang, L., et al. Molecular mechanism and approach in progression of meningioma. Frontiers in Oncology, 2020, 10: 538845. DOI: https://doi.org/10.3389/fonc.2020.538845
[23] Zhang, Y., Liu, Y., Ma, M., et al. 23-year review of spheno-orbital meningioma: Clinical, radiological, and pathological insights from 100 cases. BMC Ophthalmology, 2024, 24: 386. DOI: https://doi.org/10.1186/s12886-024-03653-w
[24] Olar, A., Wani, K. M., Sulman, E. P., et al. Mitotic index is an independent predictor of recurrence-free survival in meningioma. Brain Pathology, 2015, 25 (3): 266 – 275. DOI: https://doi.org/10.1111/bpa.12174
[25] Sahm, F., Schrimpf, D., Olar, A., et al. TERT promoter mutations and risk of recurrence in meningioma. Journal of the National Cancer Institute, 2016, 108(5): djv377. DOI: https://doi.org/10.1093/jnci/djv377
[26] Peyre, C., Dufour, A., Dhermain, M., et al. Co-targeting MAP kinase and PI3K-AKT-mTOR pathways in meningioma: Preclinical study of alpelisib and trametinib alone or in combination. Cancers, 2022, 14 (18): 4448. DOI: https://doi.org/10.3390/cancers14184448
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Transactions on Materials, Biotechnology and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
